3Altiok S, Xu M, Spiegelman BM. PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via downregulation of PP2A [J]. Genes Dev, 1997, 11 (15) : 1987- 1988.
4Lin FT, Lane MD. CCAAT/enhancer binding protein alpha is sufficient to initiate the 3T3-L1 adipocyte differentiation program [J]. Proc NatlAcad SciUSA, 1994, 91(19): 8757-8761.
5Bridler R, Umbricht D. Atypical antipsychotics in the treatment of schizophrenia[J]. Swiss Med Wkly, 2003, 133(5-6) :63-76.
6Keefe RS, Young CA, Rock SL, et al. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidnl in schizophrenia[J]. Schizophr Res, 2006, 81 ( 1 ) : 1- 15.
7McDougle CJ, Stigler KA, Erickson CA, et al. Atypical antipsychotics in children andadolescents with autistic and other pervasive developmental disorders [J]. Clin Psychiatry, 2008, 69 (4) :15-20.
8Papakostas GI, Shelton RC. Use of atypical antipsychotics for treatment-resistant major depressive disorder [J]. Curr Psychiatry Rep, 2008, 10(6):481-486.
9Pfeifer JC, Kowatch RA, DelBello MP. Pharmacotherapy of bipolar disorder in children and adolescents: recent progress [J]. CNS Drugs, 2010, 24(7):575-593.
10Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence[J]. J Clin Psychiatry, 2007(68) : 20-27.
